High-Dose Withdrawal Drug in ER Can Help Battle Opioid Addiction

Categories: For Potential Participants, [Headache, Pain, Cancer, Lymphoma, Surgery, Kidney Disease, Depression, Asthma, Allergies, Stroke, Diabetes, Breast Cancer, Migraine, Eating Disorders, Smoking, Glaucoma, Clinical Trials]

MONDAY, July 19, 2021 (HealthDay News) -- Giving high doses of buprenorphine in the emergency department is a safe and effective way of treating withdrawal symptoms in patients battling opioid addiction, according to a new study.

"Emergency departments are at the front lines of treating people with opioid use disorder and helping them overcome barriers to recovery such as withdrawal," said Dr. Nora Volkow, director of the U.S. National Institute on Drug Abuse (NIDA), which funded the study.

Lower doses of the approved opioid addiction treatment drug are the current standard of care, but some U.S. emergency departments use higher doses. Researchers said elevated doses of the medication may provide an extended period of withdrawal relief to people after being discharged from the hospital.

To assess such use, researchers analyzed 579 emergency department visits made by nearly 400 opioid-addicted adults to the Alameda Health System Highland Hospital in Oakland, Calif.

In 63% of those cases, patients received more than the usual upper limit of 12 mg of buprenorphine under the tongue. Patients were given 28 mg or more in 23% of cases.

Higher doses were safe and well tolerated, and there were no reports of side effects such as respiratory problems or drowsiness.

A small number of serious adverse events were determined to be unrelated to high-dose buprenorphine therapy, according to findings published July 15 in the journal JAMA Network Open.

"Providing buprenorphine in emergency departments presents an opportunity to expand access to treatment, especially for underserved populations, by supplementing urgent care with a bridge to outpatient services that may ultimately improve long-term outcomes," Volkow said in a NIDA news release.

Dr. Gail D'Onofrio, head of emergency medicine at Yale School of Medicine, led the research.

"This study enhances the evidence we know about emergency department buprenorphine induction, and could be a game-changer, particularly for vulnerable populations who would likely benefit from a rapid induction at the time of the visit," D'Onofrio said in the release.

More information

The U.S. Substance Abuse and Mental Health Services Administration has more on buprenorphine.

SOURCE: U.S. National Institute on Drug Abuse, news release, July 15, 2021

healthdaylogo

Copyright © 2021 HealthDay. All rights reserved.


Related Articles

For Potential Participants

Follow us on Twitter to get the latest updates on clinical research

Stay up to date with clinical research by following our Twitter account @IQVIA_Research

For Potential Participants

Results of ClinicalResearch.com community survey for 2018

We surveyed our users at the end of 2018 and here is what we learned!

For Potential Participants

Could a vaccine be used to help prevent type 1 diabetes?

Finnish clinical trials to study enterovirus vaccine, to see if it may help prevent type 1 diabetes

Want more information about clinical trials near you?

Register to get notifications about clinical trials in your area.
Register to Receive Updates